Purpose The purpose of the study was to evaluate protein expression of PD-L1 and CD20 as prognostic biomarkers of patient outcome in inflammatory breast cancer (IBC) samples. Methods PD-L1 and CD20 protein expression was measured by immunohistochemistry in 221 pretreatment IBC biopsies. + + PD-L1 was assessed in tumor cells (PD-L1 tumor cells) and tumor stromal infiltrating lymphocytes (PD-L1 TILs); CD20 was scored in tumor-infiltrating B cells. Kaplan–Meier curves and Cox proportional hazard models were used for survival analysis. + + + + Results PD-L1 tumor cells, PD-L1 TILs, and CD20 TILs were found in 8%, 66%, and 62% of IBC, respectively. PD-L1 tumor cells strongly correlated with high TILs, pathological complete response (pCR), CD20 TILs, but marginally with + + breast cancer-specific survival (BCSS, P = 0.057). PD-L1 TILs strongly correlated with high TILs, CD20 TILs, and longer disease-free survival (DFS) in all IBC and in triple-negative (TN) IBC (P < 0.035). IBC and TN IBC patients with + + + + tumors containing both CD20 TILs and PD-L1 TILs (CD20 TILs/PD-L1 TILs) showed longer DFS and improved BCSS + + (P < 0.002) than patients lacking both, or those with either CD20 TILs or PD-L1 TILs alone.
Breast Cancer Research and Treatment – Springer Journals
Published: Jun 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud